Savara Inc Business Acquisition, Pro Forma Net Income (Loss)
Savara Inc (SVRA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$18.21 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2017-11-08
- Savara Inc business acquisition, pro forma net income (loss) for the quarter ending 2017-09-30 was -$18.20M.
- Savara Inc business acquisition, pro forma net income (loss) for the quarter ending 2014-12-31 was -$7.26M.
- Savara Inc business acquisition, pro forma net income (loss) for the quarter ending 2014-09-30 was -$7.86M.
- Savara Inc business acquisition, pro forma net income (loss) for the quarter ending 2014-06-30 was -$7.00M.
- Savara Inc business acquisition, pro forma net income (loss) for fiscal 2014 was -$29.64M.
- Savara Inc business acquisition, pro forma net income (loss) for fiscal 2013 was -$24.46M.
- Savara Inc business acquisition, pro forma net income (loss) for fiscal 2011 was -$13.80M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2017-09-30 | -$18.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$18.21M 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | -$14.24K 10-Q · filed 2017-08-09 | ||||
| 2016-12-31 | -$42.56M 10-Q · filed 2017-11-08 | -$42.56K 10-Q · filed 2017-08-09 | |||
| 2014-12-31 | -$7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-24 | -$15.12M derived: sum of 2 quarters · filed 2015-03-24 | -$22.12M derived: sum of 3 quarters · filed 2015-03-24 | -$29.64M 10-K · filed 2015-03-24 | |
| 2014-09-30 | -$7.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$14.86M derived: sum of 2 quarters · filed 2014-10-31 | -$22.38M 10-Q · filed 2014-10-31 | -$24.40M derived: sum of 4 quarters · filed 2015-03-24 | |
| 2014-06-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$14.52M 10-Q · filed 2014-08-11 | -$16.54M derived: sum of 3 quarters · filed 2015-03-24 | -$23.46M derived: sum of 4 quarters · filed 2015-03-24 | |
| 2014-03-31 | -$7.52M 10-Q · filed 2014-05-05 | -$9.54M derived: sum of 2 quarters · filed 2015-03-24 | -$16.46M derived: sum of 3 quarters · filed 2015-03-24 | -$22.90M derived: sum of 4 quarters · filed 2015-03-24 | |
| 2013-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-24 | -$8.94M derived: sum of 2 quarters · filed 2015-03-24 | -$15.38M derived: sum of 3 quarters · filed 2015-03-24 | -$24.46M 10-K · filed 2015-03-24 | |
| 2013-09-30 | -$6.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$13.36M derived: sum of 2 quarters · filed 2014-10-31 | -$22.43M 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | -$6.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$15.52M 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | -$9.07M 10-Q · filed 2014-05-05 | ||||
| 2011-12-31 | -$13.80M 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |